A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol

A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol

Abstract Background The most frequently diagnosed primary brain tumor is glioblastoma (GBM). Nearly all patients experience tumor recurrence and up to 90% of which is local recurrence. Thus, increasing the therapeutic ratio of radiotherapy using hypofractionated stereotactic radiotherapy (HSRT) can...

Full description

Bibliographic Details
Main Authors: Yun Guan, Mingyuan Pan, Jun Yang, Qiuxia Lu, Liangfu Han, Ying Liu, Jing Li, Huaguang Zhu, Xiu Gong, Guanghai Mei, Xiaoxia Liu, Li Pan, Jiazhong Dai, Yang Wang, Enmin Wang, Xin Wang
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Cancer
Subjects:
Hypofractionated stereotactic radiotherapy
Newly diagnosed glioblastoma
Adjuvant chemoradiotherapy
Online Access:https://doi.org/10.1186/s12885-022-09914-5

Internet

https://doi.org/10.1186/s12885-022-09914-5

Similar Items